Gilead Q2 Profit Rises On Higher Sales Of AIDS Drugs (RTTNews) - Drug maker Gilead Sciences Inc.(GILD: News, Chart, Quote ) Thursday reported an 8.56% increase in second-quarter profit on higher sales of HIV drugs Atripla and Truvada, combined with a favorable currency exchange rate.
Gilead Q2 Profit Rises On Higher Sales Of AIDS Drugs (RTTNews) - Drug maker Gilead Sciences Inc.(GILD | Quote | Chart | News | PowerRating) Thursday reported an 8.56% increase in second-quarter profit on higher sales of HIV drugs Atripla and Truvada, combined with a favorable currency...
Tibotec Conducts Two Pivotal Phase III Clinical Trials Studying TMC278 in Treatment-Naive Adults with HIV - Once-daily TMC278, the third anti-HIV compound to be developed in Tibotec virology portfolio - YARDLEY, Pa., July 17, 2008 /PRNewswire/ -- Tibotec Pharmaceuticals Ltd.announced today that two major phase III efficacy trials examining...
Need for vigilance: two cases of abacavir allergy despite pre-treatment screening all-clear Healthcare workers and patients need to be vigilant about the possibility of an allergic reaction after starting abacavir (Ziagen), even if the HLA-B*5701 screening test is negative, emphasise investigators in separate reports in the...
42nd International Childrens Games @ Kezar Stadium Topic - Topic - Loan Online Cigarettes Medical tests Top casino Free Ringtones Medicine news Building materials Cases Intimate goods Bracelets Cheap drugs online shop Ear rings Suits Cars Rolex Replica Cheap pharmacy shop ables Autos...
Kivexa restored to first-line status in final British guidelines - but with cautions Kivexa has been restored as "an appropriate nucleoside backbone" for patients starting anti-HIV treatment in the finalised version of the British HIV Association's treatment guidelines.The published version of the guidelines also confirm...
Changes in the Risk of Death After HIV Seroconversion Compared With Mortality in the General Population: high '.....To our knowledge, no study to date has made a comparison of mortality among HIV-infected and uninfected individuals adjusted for duration of HIV infection, and our results provide estimates, hitherto unavailable, of the cumulative...
CANADA: Drug for Treating HIV May Raise Heart Attack Risk, Manufacturer Warns GlaxoSmithKline and Health Canada warned that the HIV drug abacavir and products that contain abacavir have been linked to an increased risk of heart attack.The concerns were raised by a recent Lancet study, GSK said.
GSK warns of potential heart risk for HIV drug UK drug major GlaxoSmithKline has joined with Health Canada to warn HIV patients over a possible increased risk of heart attack associated with its drug abacavir, reacting to the D:A:D study.The data, from the study published in the...
HIV Drug May Raise Heart Attack Risk - 2:30 pm ET (Toronto, Ontario) A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer is warning.GlaxoSmithKline, in conjunction...
Montrose job loss fears mount By Chris Hardy GLAXOSMITHKLINE HAS warned that redundancies are likely at its Montrose site in the near future.A review of the site's business activities has been prompted by the impact of GSK's announcement last October that it was...
Drug for treating HIV may raise heart attack risk, manufacturer warns A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada, is...
Drug for treating HIV may raise heart attack risk, manufacturer warns TORONTO - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medications manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
HIV drug linked to heart attack risk, manufacturer warns A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada, is...
GlaxoSmithKline warns that drug for treating HIV may raise heart attack risk TORONTO (AP) - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health...
Drug for treating HIV may raise heart attack risk, manufacturer warns TORONTO - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
GlaxoSmithKline, Canada issue warning on HIV drug TORONTO A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
Drug for treating HIV may raise heart attack risk, manufacturer warns TORONTO - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
GlaxoSmithKline, Canada issue warning on HIV drug TORONTO - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
GlaxoSmithKline, Canada issue warning on HIV drug GlaxoSmithKline, in conjunction with Health Canada, is advising patients taking abacavir -containing products -- sold under the brand names Ziagen, Kivexa and Trizivir -- of concerns raised by a recent study in The Lancet about the...
Canada: GlaxoSmithKline warns that drug for treating HIV may raise heart attack risk - 2:10 p.m.TORONTO (AP) - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.
GlaxoSmithKline, in conjunction...
Drug for treating HIV may raise heart attack risk, manufacturer warns GlaxoSmithKline, in conjunction with Health Canada, is advising patients taking abacavir -containing products - sold under the brand names Ziagen, Kivexa and Trizivir - of concerns raised by a recent study in The Lancet about the...
Drug for treating HIV may raise heart attack risk TORONTO - A drug used in combination with other antiretrovirals to treat HIV infection has been linked with an increased risk of heart attack, the medication's manufacturer warned Monday.GlaxoSmithKline, in conjunction with Health Canada,...
Around 10% of HIV-positive patients without hepatitis B virus or hepatitis C virus found to have signs of live Approximately 10% of HIV-positive patients who are not coinfected with hepatitis B or hepatitis C virus have liver stiffness - a reliable indicator of liver damage, according to a Spanish study presented to the Fourth International Workshop...
Gilead shares rise on analyst view for HIV drugs Gilead Sciences shares rise as analysts reiterate predictions for HIV drug sector growth NEW YORK (AP) -- Shares of drug developer Gilead Sciences Inc.rose Thursday as analysts continued to forecast growth in the HIV treatment market and...
